CAMERA: Combination Antibiotic Treatment For Methicillin Resistant Staphylococcus Aureus Bacteraemia - A Randomised Controlled Trial
Funder
National Health and Medical Research Council
Funding Amount
$1,162,248.00
Summary
MRSA (golden staph) is resistant to the most useful class of antibiotics: beta-lactams. It is more difficult to treat than antibiotic-sensitive strains. Standard treatment for MRSA is vancomycin but it has high failure rates. Although MRSA is resistant to beta-lactams, lab studies show that they enhance vancomycin’s bacterial killing when used together. CAMERA2 is an RCT comparing vancomycin alone to combination therapy (vancomycin plus flucloxacillin) for adults with MRSA blood stream infection
The True Burden Of Nosocomial Staphylococcal Disease: Genomic Markers Of Transmission Of Methicillin-sensitive And –resistant Staphylococcus Aureus
Funder
National Health and Medical Research Council
Funding Amount
$830,092.00
Summary
Staphylococcus aureus is the leading cause of hospital infection, but previous studies have only focused on the 30% caused by resistant strains (MRSA). We will trace the spread of all Staphylococcus strains in hospitals using DNA fingerprinting. This will enable us to determine why patients catch this infection, permitting interventions to reduce hospital infection. We will also examine the genomes of these bacteria to look for markers of transmission and adaptation to the hospital environment.